1 / 1
Custom Triptorelin CAS 57773-63-4 - China Suppliers & Factory for Synthetic GnRH Agonist with Sustained Release Formulations Pricelist, Service
Product Description
Triptorelin is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) agonist that works by acting continuously on pituitary GnRH receptors, initially stimulating and ultimately inhibiting the secretion of gonadotropins (LH, FSH), thereby reducing sex hormone (testosterone, estrogen) levels. Clinically, it is commonly used in acetate or papoate form, with sustained-release formulations (such as 1, 3, or 6-month injections) to achieve continuous action.
Therapeutic Areas
Oncology
- Prostate cancer: First-line endocrine therapy for advanced, metastatic, or locally high-risk prostate cancer, inhibiting tumor growth by lowering testosterone to castration levels.
- Breast cancer: Used for ovarian function suppression in premenopausal hormone receptor-positive breast cancer, in combination with other drugs to lower estrogen levels.
Gynecology & Reproductive Medicine
- Endometriosis: Relieves pain and inhibits lesion progression.
- Uterine fibroids: Preoperative reduction of fibroid size can decrease surgical difficulty and bleeding.
- Central precocious puberty: Inhibits premature puberty development and improves adult height prognosis.
- Assisted reproductive technology (ART): Used for pituitary downregulation before controlled ovarian hyperstimulation (COS).
Other Fields
- Sex-changing hormone therapy: As an initial treatment in the process of male-to-female transformation, it suppresses testosterone secretion.
- Benign prostatic hyperplasia (BPH): Used for temporary relief of severe symptoms (the risk to bone health should be weighed for long-term use).
Outlook & Development
Market and Clinical Needs
- The continued rise in the incidence of prostate and breast cancer, along with the demand for precision medicine in the field of reproductive health, supports the long-term market growth of Triptorelin.
- Long-acting formulations (such as 6-month formulations) improve patient compliance and have become the current mainstream development direction.
Innovative Formulation & Delivery
- Sustained-release technologies: Such as microspheres and implants extend the dosing interval and reduce adverse reactions at the injection site.
- Combination therapy: Combined with novel endocrine drugs (such as androgen receptor antagonists) or targeted drugs to enhance anti-tumor effects.
Expanding Indications
- Explore its potential applications in ovarian cancer and pituitary hormone-related diseases.
- By screening for individuals with specific health benefits through genetic testing or biomarkers, treatment strategies can be optimized.
Generic Drugs & Cost Control
- After patents expire, competition from generic drugs intensifies, driving down healthcare system costs and improving drug accessibility.
- Penetration in emerging markets (such as Asia and Latin America) further expands patient coverage.
Challenges & Responses
- Side effect management: Decreased bone density, hot flashes, cardiovascular risks, etc., require enhanced monitoring and the development of mitigation strategies (such as combined osteoprotective agents).
- Drug resistance issue: Some prostate cancer patients eventually progress to castration-resistant prostate cancer (CRPC), requiring exploration of sequential or combination therapies.
Frequently Asked Questions
Q
What is Triptorelin and how does it function in the body?
Triptorelin is a synthetic decapeptide GnRH agonist. It works by continuously acting on pituitary GnRH receptors, which initially stimulates and ultimately inhibits the secretion of gonadotropins, thereby effectively reducing sex hormone levels like testosterone and estrogen.
Q
How is Triptorelin typically administered?
Clinically, it is commonly used in acetate or papoate form through sustained-release formulations. These are typically administered as 1, 3, or 6-month injections to achieve a continuous therapeutic effect.
Q
What role does Triptorelin play in treating oncology patients?
In oncology, it serves as a first-line endocrine therapy for advanced or high-risk prostate cancer by lowering testosterone to castration levels. It is also used in premenopausal hormone receptor-positive breast cancer for ovarian function suppression.
Q
How is this medication utilized in gynecology and reproductive medicine?
It is used to relieve pain from endometriosis, shrink uterine fibroids prior to surgery, inhibit central precocious puberty, and for pituitary downregulation before controlled ovarian hyperstimulation in assisted reproductive technology (ART).
Q
What are the future development trends for Triptorelin formulations?
Future developments are heavily focused on long-acting formulations to improve patient compliance, utilizing sustained-release technologies like microspheres and implants, and exploring combination therapies with novel targeted drugs.
Q
What are the main clinical challenges associated with Triptorelin?
The primary challenges include managing side effects such as decreased bone density, hot flashes, and cardiovascular risks. Additionally, addressing drug resistance in patients who progress to castration-resistant prostate cancer (CRPC) requires ongoing exploration of sequential therapies.
